DESTINY-ENDOMETRIAL01 THERAPY STUDY COMBINING TRASTUZUMAB DERUXTECAN (T-DXD) AND RILVEGOSTOMIG OR PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER The DESTINY-Endometrial01 is a global, randomized (treatment assignment for the individual...

PYNNACLE STUDY THERAPY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE NEW ACTIVE SUBSTANCE REZATAPOPT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS The PYNNACLE study is a...

NOGGO S33 – Expression XX (20) Survey of female patients with gynecological tumor diseases on delivering bad news Delivering bad news is an essential part of daily medical practice, especially...

NOGGO S20 / ENGOT-gyn4 – Expression IX – (9) Long-term survival with gynecological cancer / Long-term survivors with gynecological cancers Based on the experience with Expression VI – Carolin meets...

NOGGO S18 – EMRISK Recruitment of patients with endometrial cancer has been completed for this study. Development of a Risk Prediction Model for Nausea and Vomiting During Chemotherapy What is...

ENGOT-EN29 / TroFuse-033 Therapy study on the combination of Sacituzumab Tirumotecan (SAC-TMT) and Pembrolizumab as maintenance therapy in patients with advanced or recurrent endometrial cancer The TroFuse-033 study is an...

DUOLife Observational study on first-line therapy in patients with advanced or recurrent endometrial cancer The DUOLife study is a non-interventional observational study. This means that patients receive an already planned...

ENGOT-EN20 / XPORT-EC-042Recruitment for the XPORT study was completed in January 2026. Clinical trial with Selinexor as maintenance therapy following systemic therapy in patients with p53 wild-type, advanced or recurrent...

AGO-OP.6 – ECLAT Study for patients with stage I or II endometrial cancer at high risk of recurrence – a multicenter, prospective, randomized controlled trial What is being investigated in...